These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26055693)

  • 1. Immunogenicity and safety of the new reduced-dose tetanus-diphtheria vaccine in healthy Korean adolescents: A comparative active control, double-blind, randomized, multicenter phase III study.
    Han SB; Rhim JW; Shin HJ; Kim SY; Kim JH; Kim HH; Lee KY; Kim HM; Choi YY; Ma SH; Kim CS; Kim DH; Ahn DH; Kang JH
    J Microbiol Immunol Infect; 2017 Apr; 50(2):207-213. PubMed ID: 26055693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Double-blind, Active-Controlled Phase 3 Trial.
    Choi UY; Kim KH; Lee J; Eun BW; Kim HM; Lee KY; Kim DH; Ma SH; Lee J; Kim JH
    J Korean Med Sci; 2021 Dec; 36(49):e313. PubMed ID: 34931494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a single intramuscular dose of a tetanus-diphtheria toxoid (Td) vaccine (BR-TD-1001) in healthy Korean adult subjects.
    Hong T; Chung YJ; Kim TY; Kim IH; Choe YK; Lee J; Jeon S; Han S; Yim DS
    Hum Vaccin Immunother; 2015; 11(10):2440-5. PubMed ID: 26091286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of immunogenicity and safety of the new tetanus-reduced diphtheria (Td) vaccines (GC1107) in healthy Korean adolescents: a phase II, double-blind, randomized, multicenter clinical trial.
    Rhim JW; Lee KY; Kim SY; Kim JH; Kim HH; Kim HM; Choi YY; Ma SH; Kim DH; Ahn DH; Kang JH
    J Korean Med Sci; 2013 Apr; 28(4):586-92. PubMed ID: 23579367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial [corrected] administration of tetanus toxoid (TT) versus tetanus and reduced diphtheria (Td) in pregnant women.
    Salama MM; Hady OA; Ashour W; Mostafa A; El Alkamy S; El Sayed N; El Yazeed RA
    J Clin Immunol; 2009 Jul; 29(4):524-31. PubMed ID: 19363703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a single intramuscular dose of a diphtheria-tetanus toxoid (Td) vaccine (GC1107) in Korean adults.
    Lee S; Park WB; Shin KH; Ahn DH; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Vaccine; 2011 Oct; 29(44):7638-43. PubMed ID: 21864613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
    Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
    Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
    Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
    JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of single dose of tetanus-diphtheria (Td) vaccine among non/partially immune children against diphtheria and/or tetanus, Hyderabad, India, 2007.
    Bitragunta S; Murhekar MV; Chakravarti A; Verma V; Namjoshi GS; Parekh SS; Sharma HJ; Kumar BK; Gupte MD
    Vaccine; 2010 Aug; 28(37):5934-8. PubMed ID: 20620169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV.
    Gajdos V; Vidor E; Richard P; Tran C; Sadorge C
    Vaccine; 2015 Jul; 33(32):3988-96. PubMed ID: 26087294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced immunogenicity of diphtheria and tetanus toxoids when combined with pertussis toxoid.
    Trollfors B; Taranger J; Lagergård T; Sundh V
    Pediatr Infect Dis J; 2005 Jan; 24(1):85-6. PubMed ID: 15665717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
    Weston WM; Friedland LR; Wu X; Howe B
    Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a trivalent tetanus, low dose diphtheria, inactivated poliomyelitis booster compared with a standard tetanus, low dose diphtheria booster at six to nine years of age. Munich Vaccine Study Group.
    Stojanov S; Liese JG; Bendjenana H; Harzer E; Barrand M; Jow S; Dupuy M; Belohradsky BH
    Pediatr Infect Dis J; 2000 Jun; 19(6):516-21. PubMed ID: 10877165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of diphtheria-tetanus vaccine in adults.
    Choi JH; Choo EJ; Huh A; Choi SM; Eom JS; Lee JS; Park SH; Kang JH
    J Korean Med Sci; 2010 Dec; 25(12):1727-32. PubMed ID: 21165286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in ≥ 50-year-old adults.
    Song JY; Cheong HJ; Noh JY; Choi MJ; Yoon JG; Lee SN; Kang SH; Jeong EJ; Jo YM; Kim WJ
    BMC Infect Dis; 2018 Dec; 18(1):628. PubMed ID: 30518331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
    Vesikari T; Van Damme P; Lindblad N; Pfletschinger U; Radley D; Ryan D; Vuocolo S; Haupt RM; Guris D
    Pediatr Infect Dis J; 2010 Apr; 29(4):314-8. PubMed ID: 19952980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase III Study to Evaluate the Immunogenicity and Safety of GC1107 (Adult Tetanus Diphtheria Vaccine) in Healthy Adults.
    Lee J; Choi JH; Wie SH; Park SH; Choi SM; Lee MS; Kim TH; Lee HJ; Kang JH
    J Korean Med Sci; 2019 Jan; 34(4):e31. PubMed ID: 30686952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study.
    Bühler S; Jaeger VK; Adler S; Bannert B; Brümmerhoff C; Ciurea A; Distler O; Franz J; Gabay C; Hagenbuch N; Herzog C; Hasler P; Kling K; Kyburz D; Müller R; Nissen MJ; Siegrist CA; Villiger PM; Walker UA; Hatz C
    Rheumatology (Oxford); 2019 Sep; 58(9):1585-1596. PubMed ID: 30877773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.